X0202 SCHEDULE 13G/A 0000902664-25-004997 0001974915 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 06/30/2026 0001420720 iBio, Inc. 451033708 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 Rule 13d-1(b) Vestal Point Capital, LP DE 0.00 4025000.00 0.00 4025000.00 4025000.00 N 7.9 IA PN Includes 1,425,000 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants (the "Warrants"). Ryan Wilder X1 0.00 4025000.00 0.00 4025000.00 4025000.00 N 7.9 HC IN Includes 1,425,000 shares of Common Stock issuable upon exercise of Warrants. iBio, Inc. 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of iBio, Inc. (the "Company") and shares of Common Stock issuable upon exercise of the Warrants directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock and shares of Common Stock issuable upon exercise of the Warrants directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012. The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 49,678,561 shares of Common Stock outstanding as of May 12, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 filed with the Securities and Exchange Commission on May 12, 2026, and assumes the exercise of the Warrants held by the Vestal Point Fund and Account. 7.9% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Vestal Point Capital, LP /s/ Ryan Wilder 08/14/2026 Ryan Wilder /s/ Ryan Wilder 08/14/2026